ReviewCancer science2026
Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pyroptosis, a form of programmed cell death mediated by gasdermin proteins, has gained attention for its dual role in colorectal cancer (CRC) progression and therapy. While chronic pyroptosis-driven inflammation can promote tumorigenesis, acute induction of pyroptosis in tumor cells offers promising antitumor effects. Understanding the mechanisms and implications of pyroptosis in CRC could lead to novel therapeutic strategies. Gasdermin proteins, particularly GSDMD and GSDME, are central to pyroptotic processes in CRC. GSDMD activation, often through NLRP3 inflammasome signaling or chemotherapeutic agents like simvastatin, induces pyroptosis and modulates immune infiltration. Conversely, GSDMC has been implicated in CRC progression under metabolic stress by recruiting immunosuppressive cells. Although frequently silenced in CRC, GSDME enhances sensitivity to chemoradiation and synergizes with immune checkpoint inhibitors by releasing immunostimulatory molecules. Inflammasomes, notably NLRP3 and AIM2, also play significant roles in CRC pathogenesis through pyroptosis and cytokine secretion. NLRP3 activation exacerbates tumor growth via inflammatory pathways, while AIM2 exerts tumor-suppressive effects, especially in BRAF-mutant CRC. The gut microbiota further influences inflammasome activity, with certain strains promoting chemoresistance and others enhancing antitumor immunity. Therapeutically, inducing pyroptosis synergizes with conventional therapies and immunotherapies, overcoming apoptosis resistance and resensitizing tumors. Pyroptosis releases tumor antigens and damage-associated molecular patterns, recruiting cytotoxic lymphocytes and natural killer cells, thereby remodeling the immunosuppressive microenvironment. Pyroptosis represents a double-edged sword in CRC, offering both challenges and opportunities. Harnessing its antitumor potential while mitigating pro-tumorigenic inflammation requires innovative strategies. Future research should focus on elucidating the isoform-specific roles of gasdermins, optimizing therapeutic approaches to induce pyroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.